Prostaglandin production in mouse mammary tumour cells confers invasive growth potential by inducing hepatocyte growth factor in stromal fibroblasts by Matsumoto-Taniura, N et al.
Interactions between epithelium and mesenchyme (or stroma)
mediate crucial aspects of normal development, tissue morpho-
genesis and neoplasia. In tissue recombination, growth, differenti-
ation and morphogenesis of developing epithelia are regulated
either inductively or permissively by neighbouring mesenchyme,
including pancreas, salivary gland, kidney, mammary gland, etc.
(Grobstein, 1967; Sakakura, 1991; Birchmeier and Birchmeier,
1993). Host stromal influence on epithelial neoplasia and malig-
nant progression of carcinoma cells have also been noted in
various tumours, including cancers in prostate, stomach, skin, oral
cavity, mammary gland, etc. (van den Hoof, 1988). In vivo growth
of certain carcinoma cells was markedly accelerated by a broad
spectrum of fibroblasts, and in vitro invasiveness of several carci-
noma cells was induced by co-cultivation with stromal fibroblasts
(Picard et al, 1986; Grey et al, 1989; Camps et al, 1990;
Matsumoto et al, 1994). Although matrix metalloproteinases,
growth factors and cell motility factors are implicated in
tumour–stromal interactions, less is known of molecular mecha-
nisms which confer invasive growth of cancer cells through
interactions with surrounding stroma.
Hepatocyte growth factor (HGF), originally identified as a
potent mitogen for hepatocytes (Nakamura et al, 1984), is a
kringle-containing growth factor which has mitogenic, motogenic
and morphogenic activities in a wide variety of cells (Nakamura
et al, 1989; Montesano et al, 1991; Zarnegar and Michalopoulos,
1995; Matsumoto and Nakamura, 1997). HGF specifically acti-
vates the Met/HGF receptor of heterodimeric tyrosine kinase,
which is expressed on a wide variety of epithelial cells, endothelial
cells and several mesenchymal cells. During normal development,
HGF supports growth, migration and morphogenesis of organs and
tissues, including the liver, kidney, tooth, limb muscle, lung and
mammary gland, as a mesenchymal-derived paracrine factor
(Santos et al, 1994; Bladt et al, 1995; Niranjan et al, 1995; Soriano
et al, 1995; Yang et al, 1995; Tabata et al, 1996; Ohmichi et al,
1998). Likewise, HGF plays a ‘trophic’ role to enhance regenera-
tion of organs, including the liver, kidney and lung, as a stromal-
derived factor (see review, Matsumoto and Nakamura, 1997).
Thus, HGF seems to be a mediator in epithelial–mesenchymal
(or –stromal) interactions during tissue formation and repair.
Accumulating evidence shows that HGF is likely to play a role
in tumour progression through tumour and host stromal interac-
tions (Seslar et al, 1993; Rosen et al, 1994; Matsumoto et al, 1996;
Nakamura et al, 1997). As scatter factor, originally identified as
fibroblast-derived cell motility factor for epithelial cells (Stoker et
al, 1987), proved to be identical with HGF (Furlong et al, 1991;
Konishi et al, 1991; Weidner et al, 1991), HGF potently stimulates
migration and invasion of various types of cells, including carci-
noma cells (Weidner et al, 1990; Jiang et al, 1993; Matsumoto
et al, 1994, 1996; Nakamura et al, 1997), and autocrine activation
of Met results in increased tumourigenicity and metastasis
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Summary Interactions between stromal and mammary tumour cells play a crucial role in determining the malignant behaviour of tumour cells.
Although MMT mouse mammary tumour cells do not produce hepatocyte growth factor (HGF), addition of conditioned medium (CM) from
MMT cells to cultures of human fibroblasts derived from skin and breast tissues stimulated the production of HGF, thereby indicating that MMT
cells secrete an inducing factor for HGF. This HGF-inducing factor, purified from MMT-derived CM, proved to be prostaglandin E2 (PGE2).
Consistently, treatment of MMT cells with indomethacin, an inhibitor of cyclooxygenase, abolished this HGF-inducing activity in MMT-derived
CM, while treatment of MMT cells with HGF stimulated cell growth and cell motility. Likewise, HGF strongly enhanced urokinase-type
plasminogen activator activity and invasion of MMT cells through Matrigel: a 15-fold stimulation in the invasion of MMT cells was seen by
HGF. Finally, MMT cells in the upper compartment were co-cultivated with fibroblasts in the lower compartment of the Matrigel chamber, HGF
levels in the co-culture system exceeded the level in fibroblasts alone and suppression occurred with exposure to indomethacin. Together with
increase in the HGF level, the invasion of MMT cells was enhanced by co-cultivation with fibroblasts, whereas the increased invasion of MMT
cells was significantly inhibited by an anti-HGF antibody and by indomethacin. These results indicate mutual interactions between MMT cells
and fibroblasts: MMT-derived PGE2 plays a role in up-regulating HGF production in fibroblasts, while fibroblast-derived HGF leads to invasive
growth in MMT cells. The mutual interactions mediated by HGF and prostaglandins may possibly be a mechanism regulating malignant
behaviour of mammary tumour cells, through tumour–stromal interactions.
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(Bellusci et al, 1994; Jeffers et al, 1996). HGF is an angiogenic
factor and plays a role in tumour angiogenesis (Bussolino et al,
1992; Grant et al, 1993; Lamszus et al, 1997). Fibroblast-derived
factor, which induces in vitro invasion of carcinoma cells, proved
to be HGF (Matsumoto et al, 1994). On the other hand, various
types of carcinoma cells secrete soluble factors that regulate the
production of HGF in stromal fibroblasts (Seslar et al, 1993;
Matsumoto et al, 1996; Nakamura et al, 1997). These results
suggest the presence of the mutual interaction between carcinoma
cells and fibroblasts, as mediated by tumour-derived regulator for
expression of HGF and fibroblast-derived HGF, which affects
invasive growth of tumour cells.
During a search for tumour-derived inducers for expression of
HGF in fibroblasts, we found that the murine mammary carcinoma
cell line, MMT cells, secreted a distinct type of HGF-inducer for
fibroblasts. We now report that the MMT-derived HGF-inducer is
prostaglandin E2 (PGE2), and the biological significance of PGE2
in invasive growth of MMT cells was investigated.
MATERIALS AND METHODS
Cell culture
MMT mouse mammary carcinoma cells were obtained from the
Human Science Research Resources Bank, Japan. MMT cell line
was originally established from a spontaneous mammary tumour
which arose in a (C57BL ´ Af)F1 female mouse (Sykes et al,
1968). MMT cells are epithelial in appearance and produce mouse
mammary tumour virus, implicating that MMT cells were
originally transformed by mammary tumour virus infection (Sykes
et al, 1968). MMT cells were cultured in modified Eagle’s medium
(MEM) supplemented with 10% calf serum. Normal or tumour
associated human fibroblasts were, respectively, proliferated
outward from the skin and breast cancer tissues obtained during
surgery and the cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal calf serum (FCS).
Growth factors and antibodies
Human recombinant HGF was purified from culture medium of
Chinese hamster ovary cells transfected with expression plasmid
for human HGF cDNA (Nakamura et al, 1989; Seki et al, 1990).
The purity of HGF exceeded 98%, as determined by sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
and protein staining. Human recombinant platelet-derived growth
factor (PDGF) and bovine recombinant basic fibroblast growth
factor (bFGF) were obtained from Toyobo Co. (Osaka, Japan).
Human recombinant interleukin-1a (IL-1a) and IL-1b were
obtained from Genzyme Co. (Boston, MA, USA). A recombinant
IL-1 receptor antagonist was obtained from R&D systems Co.
(Minneapolis, MN, USA) and monoclonal anti-human epidermal
growth factor (EGF) receptor antibody were obtained from
Genzyme Co. (Boston, MA, USA). Polyclonal anti-PDGF anti-
body was obtained from Promega (Madison, WI, USA) and mono-
clonal anti-bFGF (Matsuzaki et al, 1989) was a kind gift from Dr
K Nishikawa (Kanazawa Medical College). Polyclonal antibody
against human HGF was prepared from the serum
of a rabbit immunized with human recombinant HGF. IgG was
purified using protein A-Sepharose (Pharmacia, Uppsala, Sweden)
and anti-human HGF IgG (1 mg ml–1) completely neutralized
biological activities of 1 ng ml–1 human HGF.
Measurement of cell growth and scattering
To measure cell growth, MMT cells were seeded on 12-well plates
(Costar, Cambridge, MA, USA) at a density of 1.1 ´ 103 cells cm–2
and cultured for 24 h. After washing with MEM, the cells were
cultured for 4.5 days in serum-free MEM in the absence or
presence of HGF. The medium was changed on day 3.
For the measurement of cell scattering, MMT cells were seeded
on 24-well plates (Costar, Cambridge, MA, USA) at a density of
2.8 ´ 103 cells cm–2 and cultured for 48 h. After medium was
changed, HGF was added and the cells were cultured for 18 h.
In-vitro invasion assay
In-vitro invasion of MMT cells was measured using a Matrigel
invasion chamber (Collaborative Biomedical Products, Bedford,
MA, USA). MMT cells were seeded onto the upper compartment
of a Matrigel chamber at a density of 6.7 ´ 104 cells cm–2 and
cultured in MEM containing 10% FCS. HGF was added to the
lower compartment and cells were cultured for 15 h. Invasive cells
penetrating through Matrigel components and pores to the under-
side of the membrane were stained with haematoxylin and eosin,
viewed microscopically and counted.
For co-cultivation of MMT cells and fibroblasts, human dermal
fibroblasts were initially plated onto the lower compartment of a
Matrigel invasion chamber, at a density of 5 ´ 104 cells cm–2 and
cultured for 24 h. The medium was changed to fresh medium
composed of MEM/DMEM (1/1) containing 5% FCS and 5% calf
serum. The MMT cells were seeded onto the upper compartment
at a density of 6.7 ´ 104 cells cm–2. The cells were cultured
for 48 h in the absence or presence of preimmune IgG, anti-
human HGF IgG (10 mgm l –1), 10–7 M indomethacin or 10–7 M
indomethacin plus 10–6 M PGE2.
Measurement of HGF production in fibroblasts
Human fibroblasts were seeded on a 48-well plate (Costar,
Cambridge, MA, USA) at a density of 5 ´ 104 cells cm–2 and
cultured for 24 h. After replacing the medium with DMEM
supplemented with 1% FCS and 2 mg ml–1 heparin, test samples
were added to each well. Following a 24 h culture, the concentra-
tion of HGF in the medium was measured using enzyme-linked
immunosorbent assay (ELISA), as described elsewhere
(Matsumoto et al, 1996).
Measurement of PGE2 production in MMT cells
Subconfluent MMT cells were washed twice with serum-free
MEM, cultured in serum-free MEM, with or without indomethacin
for 24 h and the conditioned medium (CM) was collected. The
concentration of PGE2 in the medium was determined using an
ELISA kit obtained from Cayman Co. (Ann Arbor, MI, USA).
This ELISA specifically detects PGE2, not other prostaglandins.
Zymographies for gelatinase and urokinase-type
plasminogen activator
Subconfluent MMT cells were cultured in serum-free MEM, with
or without HGF for 24 h, and the CM was collected. For the
measurement of gelatinase activity, samples were subjected to
SDS-PAGE, using a 10% polyacrylamide gel containing 1 mg ml–1196 N Matsumoto-Taniura et al
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gelatin. After electrophoresis, the gel was washed in 2.5% Triton
X-100, and incubated in 50 mM Tris–HCl buffer (pH 8.0)
containing 0.5 mM calcium chloride and 1 mM zinc chloride for
24 h at 37°C. The gel was stained with Coomassie brilliant blue
and photographed. For the measurement of urokinase-type plas-
minogen activator (u-PA), culture supernatants were prepared and
analysed as described elsewhere (Vassalli et al, 1984).
Purification of MMT-derived HGF-inducer
After MMT cells grew to confluency, the culture medium was
changed to serum-free medium and the cells were cultured for a
further 48 h. CM was concentrated by lyophilization and subjected
to molecular sieve chromatography, using a Sephadex G-25
column (Pharmacia Biotech, Uppsala, Sweden), equilibrated with
15 mM phosphate buffer (pH 7.2), 0.15 M sodium chloride. Active
fractions were pooled, concentrated by lyophilization, and applied
to reverse phase high-performance liquid chromatography (RP-
HPLC) with a C18 column. Absorbed materials were eluted by a
concentration gradient of acetonitrile. The eluate was concentrated
by vacuum centrifugation and dissolved in H2O.
RESULTS
Characterization of MMT-derived HGF-inducer
HGF-inducing activity was determined by measuring HGF
production in cultures of human skin fibroblasts after addition of
CM from MMT mouse mammary tumour cells. The addition of
MMT-derived CM stimulated HGF production in cultures of
fibroblasts (Figure 1A): a four- to fivefold increase in HGF level in
fibroblast cultures occurred when CM was added at 50% (v/v),
whereas its potential to stimulate HGF-production was less than
that of 0.5 ng ml–1 IL-1b. Since the MMT-derived CM itself did
not contain a detectable level of HGF (not shown), our observa-
tions indicated that MMT cells secrete a factor which stimulates
the production of HGF in normal human fibroblasts.
Our previous studies demonstrated that several types of tumour
cells secrete inducing factors for HGF production in fibroblasts,
and these factors were identified to be IL-1a, IL-1b, PDGF and
bFGF (Matsumoto et al, 1996; Nakamura et al, 1997). We there-
fore asked whether the MMT-derived HGF-inducer is identical to
one of these factors. MMT-derived CM was added to fibroblast
cultures and the cells were cultured in the absence or presence of
an IL-1 receptor (IL-1R) antagonist or an antibody against PDGF,
bFGF or EGF-R. IL-1R antagonist and these antibodies almost
completely inhibited the respective activities of IL-1a, IL-1b,
PDGF, bFGF and TGF-a to stimulate HGF production (not
shown). The stimulatory effect of MMT-derived CM on HGF
production was slightly inhibited by the IL-1R antagonist but was
hardly inhibited by any of the antibodies (Figure 1B). This indi-
cates that the HGF-inducer derived from MMT cells is distinct
from these cytokines and growth factors.
MMT-derived CM was concentrated by lyophilization,
subjected to molecular sieve chromatography, using a Sephadex
G-25 column, and the eluted fractions were tested to determine if
they would stimulate HGF production in fibroblast cultures
(Figure 2). HGF-inducing activity was eluted as two distinct
peaks: the major peak eluted at positions of Mr around 900 and the
minor peak eluted near Vo position.
Identification of MMT-derived HGF inducer
We repeated molecular sieve chromatography and active fractions
from CM were pooled and lyophilized. The pooled material
was dissolved in H2O, dialysed against H2O, and subjected to
RP-HPLC with a C18 column (Figure 3A). The adsorbed materials
were eluted with a concentration gradient of acetonitrile and the
eluted fractions were subjected to assay. When the pooled material
from CM of MMT cells was applied to RP-HPLC, HGF-inducing
activity was seen as a single peak of fraction 55. It is worth noting
that the HGF-inducing activity eluted after RP-HPLC was compa-
rable to that seen with 0.5 ng ml–1 IL-1b (a dose which gives the
maximal activity of IL-1b) and it was approximately twofold
higher than that of the maximal activity seen in the pooled
materials subjected to RP-HPLC. The potentiation of HGF-
inducing activity after RP-HPLC means that an inhibitory factor
which suppresses HGF-inducing factor in MMT-derived CM was
dissociated during RP-HPLC.
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Figure 1 Stimulatory effect of conditioned medium (CM) from MMT cells on
HGF production in human skin fibroblasts. (A) Stimulation of HGF production
by MMT-derived CM. (B) Effects of antibodies and an antagonist against
polypeptide HGF-inducers. Fibroblasts were seeded on 48-well plates and
cultured for 24 h. After replacing the medium with fresh DMEM
supplemented with 1% FCS and 2 mg ml–1 heparin, CM from MMT cells was
added in the absence or presence of antibodies and an antagonist. The cells
were cultured for 24 h and the concentration of HGF in the medium was
measured by ELISA. Values represent the mean of triplicate measurements
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Figure 2 Elution profile of HGF-inducing activity from MMT-derived CM in
molecular sieve chromatography with a Sephadex G-25 column. The CM
was concentrated by lyophilization and applied to a Sephadex G-25 column
equilibrated with 15 mM phosphate buffer (pH 7.2), 0.15 M sodium chloride.
Eluted fractions were subjected to assay for HGF-inducing activity, using
human skin fibroblastsTumour invasion regulated by PGE2-HGF loop 197
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The above results indicated that the MMT-derived HGF-inducer
was a lipophilic molecule with a relatively low Mr, and we specu-
lated it might be prostaglandins. We therefore tested whether
various prostaglandins might stimulate HGF production in the
fibroblasts. Among prostaglandins tested, including prostaglandin
D2 (PGD2), PGE1, PGE2, PGF2a, PGI2, staurosporin A2 and throm-
boxan B2, PGE1 and PGE2 patently stimulated HGF production in
the fibroblasts (not shown). We therefore applied authentic PGE1
and PGE2, respectively, to a C18 RP-HPLC column followed by
elution under the same conditions as used for MMT-derived HGF-
inducer (Figure 3B). PGE1 eluted as a major single peak at fraction
57 and HGF-inducing activity in the elute coincided with the peak,
while PGE2 eluted at fraction 55, thus, coinciding with its bio-
logical activity to stimulate HGF production. Taken together, these
results strongly suggest that the HGF-inducer secreted from MMT
cells is PGE2.
To obtain further evidence that the HGF-inducer derived from
MMT cells is PGE2, MMT cells were cultured in the presence of
indomethacin, a specific inhibitor for cyclooxygenase, and HGF-
inducing activity in the CM was measured. HGF-inducing activity
in CM from MMT cells was almost completely inhibited by expo-
sure to indomethacin, in a dose-dependent manner (Figure 4A).
Likewise, HGF-inducing activity in CM of MMT cells treated
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Figure 3 Elution profile of HGF-inducing activity from MMT-derived CM (A)
and PGE1 and PGE2 (B) in C18 RP-HPLC. Pooled active fractions after
molecular sieve chromatography were concentrated and subjected to C18
RP-HPLC. The absorbed materials were eluted with a concentration gradient
of acetonitrile and eluted fractions were subjected to assay for HGF-inducing
activity
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Figure 5 Stimulatory effects of MMT-derived CM (A) and PGE2 (B) on HGF
production in human fibroblasts derived from normal breast and breast
carcinoma tissues. Values represent the mean ± s.d. of triplicate
measurements
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Figure 6 Enhancement of cell growth (A) and cell scattering (B) of MMT
cells by HGF. For measurement of cell growth, MMT cells were cultured for
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Figure 7 Stimulatory effect of HGF on in vitro invasion of MMT cells.
(A) Appearance of invasive cells migrating under the membrane. (B) Dose-
dependent enhancement of invasion of MMT cells by HGF. MMT cells were
seeded on Matrigel basement membrane components for 2 days in the
absence or presence of HGF. Invasive cells invading through Matrigel and 8-
mm pores of the filter membrane to the underside of the membrane were
stained with haematoxylin and counted, as viewed microscopically
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Figure 8 Regulation of u-PA and gelatinase activities in MMT cells by HGF.
u-PA activity (A) and gelatinase activity (B) were measured in CM from MMT
cells. MMT cells were cultured for 24 h in the absence or presence of HGF,
and CM was subjected to SDS-PAGE. u-PA and gelatinase activities were
respectively measured using zymographical methodsTumour invasion regulated by PGE2-HGF loop 199
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with 10–7 M indomethacin was measured after molecular sieve
chromatography with Sephadex G-25 (Figure 4B). The elution
profile clearly indicated that the HGF-inducing activity in the
major peak corresponding to Mr around 900 Da was almost
completely diminished, whereas the HGF-inducing activity in the
minor peak which eluted near Vo position was not inhibited. We
next measured PGE2 production by MMT cells, using a specific
ELISA (Figure 4C). During 24-h culture, PGE2 level in the CM of
MMT cells reached 242 ng ml–1 (6.9 ´ 10–7 M). Furthermore, the
addition of indomethacin dose-dependently inhibited PGE2
production in MMT cells and PGE2 production in the cells treated
with 10–7 M indomethacin was only 1/30 of that seen in control
culture. Together with these results, we concluded that the HGF-
inducer from MMT cells was PGE2.
Since the MMT cells originated from mammary tissue, we
asked if HGF production in human fibroblasts derived from
normal breast and breast carcinoma tissues in a patient with breast
carcinoma was regulated by MMT-derived CM and PGE2
(Figure 5). The basal HGF production in fibroblasts from normal
and breast carcinoma tissues was 3.74 ± 0.12 ng ml–1 and
5.27 ± 0.14 ng ml–1 respectively. Although HGF production in
fibroblasts from breast carcinoma tissue was higher than that in
normal breast fibroblasts, HGF production in fibroblasts from
breast carcinoma tissue was not consistently higher than that in
normal breast fibroblasts to some extent, it was not consistent (not
shown). HGF production in breast fibroblasts from both normal
and tumour tissues was dose-dependently stimulated by both
MMT-derived CM (Figure 5A) and PGE2 (Figure 5B). Similar
stimulatory effects were seen in other human breast fibroblasts
derived from other patients with breast cancer (not shown).
Biological effects of HGF on MMT cells
On the basis of our data that MMT cells secrete PGE2 as a potent
HGF inducer for fibroblasts, we assume that MMT cells might
stimulate HGF production in fibroblasts and fibroblast-derived
HGF might affect growth, migration and invasion of MMT cells.
Interactions of tumour cells with stromal fibroblasts have a signifi-
cant effect on the malignant behaviour of carcinoma cells
(Lippman and Dickson, 1990; Sakakura, 1991; Wernert, 1997).
When HGF was added to cultures of MMT cells, HGF stimulated
proliferation of the cells, in a dose-dependent manner (Figure 6A).
The maximal activity with a 2.5-fold increase in cell number was
seen with 3–10 ng ml–1 HGF. In addition to cell growth stimula-
tion, HGF stimulated migration of the cells. Addition of HGF in
MMT cells in monolayer culture induced scattering of the cells
(Figure 6B), thereby indicating that HGF stimulates motility of
MMT cells.
To determine if HGF would affect invasion of MMT cells, the
cells were cultured in a Matrigel invasion chamber in the absence
or presence of HGF (Figure 7A). Although some cells invaded
through the Matrigel basement membrane components and
migrated under the filter membrane in the absence of HGF, the
addition of HGF strongly enhanced invasion of these cells. The
maximal effect by 15-fold stimulation was seen with 5 ng ml–1
HGF, while at a higher concentration, the number of invading cells
decreased (Figure 7B). Therefore, HGF may stimulate the inva-
sion of MMT cells through the basement membrane.
Since the process of invasion requires increased activities in
both cell migration and extracellular proteolysis, we investigated
the effects of HGF on extracellular protease activities in MMT
cells. HGF-treatment strongly increased u-PA activity, in a dose-
dependent manner (Figure 8). On the other hand, although MMT
cells secreted 92 kDa gelatinase (MMP-9), this secretion remained
unchanged with HGF-treatment (Figure 8).
In vitro invasion through tumour–stromal interaction
Based on findings that MMT cells secrete PGE2 as an inducer for
HGF production in fibroblasts, while HGF strongly stimulates
invasion of MMT cells, we set up a co-culture method, using a
Matrigel invasion chamber in which fibroblasts were cultured in
the lower compartment and MMT cells were cultured in the upper
compartment (Figure 9A). This co-culture system mimics the
Inner cup
MMT cells
Matrigel
Filter
membrane
Fibroblasts
Outer cup
A
4
3
2
1
0
H
G
F
 
(
n
g
/
m
l
)
MMT alone
MMT + HGF
fibroblasts alone
None
anti-HGF
Indomet.
Indomet.
+ PGE2
Co-culture of MMT
+ fibroblasts
MMT alone
MMT + HGF
None
anti-HGF
Indomet.
Indomet.
+ PGE2
Co-culture of MMT
+ fibroblasts
0
100
200
300
I
n
v
a
d
e
d
 
c
e
l
l
s
 
(
c
e
l
l
s
 
p
e
r
 
f
i
e
l
d
)
C B
Figure 9 In vitro invasion of MMT cells cocultured with fibroblasts. (A) Diagram showing method we used to co-culture MMT cells and fibroblasts. (B) HGF
concentration in co-culture system of MMT cells and fibroblasts. (C) Number of invasive MMT cells in the co-culture of MMT cells and fibroblasts. Human
fibroblasts were initially seeded on 24-well plates, and MMT cells were seeded in the upper compartment of a 24-well Matrigel invasion chamber. Cells were
cultured for 48 h in the absence or presence of 5 ng ml–1 HGF, 10 mg ml–1 anti-HGF IgG, 10–7 M indomethacin, or 10–7 M indomethacin plus 10–6 M PGE2, and the
number of invasive cells was enumerated200 N Matsumoto-Taniura et al
British Journal of Cancer (1999) 81(2), 194–202 © 1999 Cancer Research Campaign
tumour–stromal interaction through basement membrane compo-
nents. Without co-cultured MMT cells, basal HGF production in
fibroblasts was 0.4 ng ml–1 during 48-h culture, but the production
of HGF was stimulated to 1.1 ng ml–1 by co-cultivation with MMT
cells (Figure 9B). HGF was undetectable when anti-HGF IgG was
added to this culture. The addition of 10–7 M indomethacin
decreased the HGF to near basal levels seen in the culture of
fibroblasts alone, indicating that the increase in HGF level under
this co-culture condition was probably due to PGE2 secreted from
MMT cells. Simultaneous addition of 10–6 M PGE2 and 10–7 M
indomethacin to this culture again increased HGF levels 3.1-fold
higher than seen in the culture with 10–7 M indomethacin alone.
When MMT cells were cultured alone, the addition of 5 ng ml–1
HGF stimulated the invasion of MMT cells to a 2.6-fold higher
level than seen without HGF (Figure 9C). The addition of
10 mg ml–1 anti-HGF IgG almost completely neutralized the inva-
sion of MMT cells stimulated by 5 ng ml–1 HGF, while anti-HGF
IgG alone had no effect on invasion of MMT cells (not shown).
Co-cultivation of MMT cells with fibroblasts increased the
number of invading cells by a 3.9-fold higher level than that seen
without fibroblasts. The number of invading cells in the co-culture
was higher than that seen with MMT cells alone in the presence of
5 ng ml–1, even though the HGF level in the co-culture was only
1.1 ng ml–1 (Figure 9B). This finding suggests that fibroblasts
might secrete a factor(s) distinct from HGF and such a factor(s)
might stimulate invasion of the cells, in this co-culture system (see
below). Importantly, the addition of anti-HGF strongly inhibited
invasion of the cells to the level seen in the culture of MMT cells
alone. Likewise, the addition of 10–7 M indomethacin inhibited
invasion of MMT cells, but this inhibitory effect was less than that
seen with anti-HGF antibody, because the basal HGF production
in fibroblasts was retained, even in the presence of indomethacin.
Moreover, the addition of 10–6 M PGE2 to this co-culture in the
presence of 10–7 M indomethacin again stimulated invasion of
MMT cells, consistent with the increase in HGF level in this
culture condition. Therefore, in this co-culture system, the mutual
interaction between MMT cells and fibroblasts was evident: HGF
production in fibroblasts is stimulated by PGE2 secreted from
MMT cells, while fibroblast-derived HGF in turn strongly stimu-
lates invasion of MMT cells.
Since the enhanced invasion of MMT cells in the co-culture
with fibroblasts was inhibited to the basal level by anti-HGF anti-
body, the above fibroblast-derived factor(s) distinct from HGF is
likely to depend on the co-existence of HGF, in stimulating
invasion of MMT cells. Although we have yet to specify such
a fibroblast-derived factor(s), one possible explanation is that
fibroblasts might produce pro-matrix metalloproteinases (pro-
MMPs), and the activation of pro-MMPs might depend on
tumour-derived proteinase such as u-PA. HGF strongly stimulated
u-PA activity in MMT cells (Figure 8).
DISCUSSION
HGF is a mesenchymal- or stromal-derived factor which elicits
mitogenic, motogenic and morphogenic responses in a wide variety
of cells (Zarnegar and Michalopoulos, 1995; Matsumoto and
Nakamura, 1997). During development of the mammary gland,
HGF is involved in branching duct formation in mammary gland
epithelial cells (Niranjan et al, 1995; Soriano et al, 1995; Yang et al,
1995). A fibroblast-derived mitogen for mammary gland epithelial
cells was identified to be HGF (Sasaki et al, 1994), indicating that
HGF affects growth of mammary epithelial cells as a stromal-
derived paracrine factor. It is therefore conceivable that HGF func-
tions as a mediator in tumour–stromal interactions in breast cancer,
leading to the acquisition of malignant phenotypes in breast cancer
cells. In the present study, we found that HGF potently stimulates
migration and invasion of MMT mouse mammary carcinoma cells,
as well as stimulating their growth. Of importance in our study is the
finding that there is a mutual interaction between MMT carcinoma
cells and fibroblasts, as mediated by MMT-derived PGE2 and
fibroblast-derived HGF. MMT-derived PGE2 up-regulates HGF
production in fibroblasts, while fibroblast-derived HGF stimulates
growth and invasion of MMT cells. There have been reports that
PGE2 levels are elevated in malignant human breast tumours and
murine mammary tumours (Rolland et al, 1980; Karmali et al, 1983;
Bennett et al, 1989). In-vitro studies using tissue explants or human
breast tumour cells in primary culture also revealed higher PGE2
production by tumour cells from malignant tissue than that seen in
cells from benign tumour and normal tissues (Watson and Chuah,
1992). Together with these results, one possible mechanism is that
breast carcinoma cells secrete PGE2, the elevated PGE2 stimulates
HGF production in stromal fibroblasts, and fibroblast-derived HGF
induces invasive growth of breast carcinoma cells. We also found
that HGF strongly increased u-PA activity in MMT cells. Since
involvement of u-PA-induction in tumour invasion has been demon-
strated in various cancer cells (Vassalli and Pepper, 1994) and induc-
tion of u-PA by HGF correlates with in vitro invasiveness and in
vivo metastatic potential (Jeffers et al, 1996), increase in u-PA
activity by HGF could possibly be one critical event, leading to
increased invasive potential in MMT cells.
Previous studies noted that various types of cancer cells secrete
stimulatory factors for production of HGF in distinct types of
fibroblasts and such tumour-derived HGF-inducers were identified
to be polypeptide cytokines and growth factors such as IL-1a,
IL-1b, bFGF and PDGF (Matsumoto et al, 1996; Nakamura et al,
1997). It should be emphasized that we here have newly identified
PGE2 to be a non-polypeptide HGF-inducer derived from tumour
cells. Previous studies indicated that some prostaglandins (PGE1,
PGE2 and PGI2 analogue) stimulate HGF production by activating
gene expression of HGF rather than by regulating post-transcrip-
tional processes (Matsumoto et al, 1995). On the other hand expres-
sion of HGF gene is up-regulated by at least two distinct signalling
pathways: A-kinase-mediated and C-kinase-mediated pathways
(Matsunaga et al, 1994; Matsumoto et al, 1995). Although we did
not investigate the pathway through which PGE2 exhibits HGF-
inducing activity, the A-kinase-mediated pathway is likely to be
responsible, for the following reasons: (1) PGE2 stimulates both
cAMP levels and HGF production through the EP2/EP4
prostaglandin receptor which stimulates adenylate cyclase
(Takahashi et al, 1996); (2) stimulatory effect on HGF production
in fibroblasts is additive/synergistic between PGE2 and an activator
of C-kinase, but not additive between PGE2 and a cAMP analogue
which activates A-kinase (Matsumoto et al, 1995).
Most mammary carcinoma cells and many types of other carci-
noma cells do not produce HGF in vitro (Jiang et al, 1993; Byers
et al, 1994; Rosen et al, 1994; Nakamura et al, 1997; our unpublished
data), whereas many different types of fibroblasts, including
mammary fibroblasts produce moderate to high levels of HGF
(Stoker et al, 1987; Seslar et al, 1993; Rosen et al, 1994). Thus,
stromal cells seem to be a major source of HGF within tumour
tissues. On the other hand, there are data that HGF protein and
mRNA are expressed in mammary carcinoma cells (Wang et al,Tumour invasion regulated by PGE2-HGF loop 201
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1994; Rahimi et al, 1996; Tuck et al, 1996; Jin et al, 1997a), as well
as in stromal cells. The expression of HGF is elevated in mammary
carcinomas, in comparison with findings in benign hyperplasia (Jin
et al, 1997a; Tuck et al, 1996), and HGF levels in breast cancer tissue
are a strong predictor of a recurrence in breast cancer patients
(Yamashita et al, 1994; Nagy et al, 1996; Yao et al, 1996). The lack of
potential of cultured mammary carcinoma cells to produce HGF may
possibly reflect the absence of a stimulatory cofactor required for
HGF production in tumour tissues, or a characteristic change of the
cells due to consequences of serial cultivation. Although this issue
remains to be addressed, the source of HGF in malignant mammary
carcinomas may be extended to tumour components, as well as
stromal components in more progressed breast cancers. It seems
likely that increased PGE2 production in malignant breast cancer
cells leads to an increased HGF production in the tumour microenvi-
ronment, at least in stromal cells in close proximity to tumour cells.
A number of studies indicate that compounds known as non-
steroidal anti-inflammatory drugs (NSAIDs) reduce the incidence
of cancers, including colon, bladder, lung and breast cancers
(Marnett, 1995; Rosenberg, 1995). Although NSAIDs inhibit
cyclooxygenase which catalyses the biosynthesis of PGH2, precur-
sors for prostanoids such as prostaglandins, the mechanisms by
which inhibition of PG synthesis contribute to decreased carcino-
genesis in colon and some other tissues have yet to be defined. In
addition to breast cancer, studies have shown that colon cancer
tissues produce a large amount of PGE2 (Narisawa et al, 1990).
Moreover, our very recent study showed that a potent stimulatory
effect of IL-1 on HGF production in fibroblasts was mediated via
PGE2 production and was almost completely abrogated by
indomethacin (unpublished data). IL-1 (IL-1a and IL-1b) are HGF-
inducers derived from various tumour cell lines (Matsumoto et al,
1996; Nakamura et al, 1997), and the elevated expression of IL-1 in
various tumour tissues has been noted (Colasante et al, 1997; Jin et
al, 1997b). These results provide insight into one possible mecha-
nism of how the inhibition of PG synthesis by NSAIDs is involved
in reduced carcinogenesis. Active PG production in stromal cells as
well as in tumour cells in a tumour microenvironment stimulates
HGF production, an event which may lead to acquisition of inva-
sive growth potential in cancer cells, and to an increased likelihood
of development of a malignant tumour. This hypothesis is now
being tested using colon cancer cells.
The neoplastic cells of breast carcinomas are often embedded in
stromal tissues, an event which may be important to control their
growth, invasion and metastasis. Indeed, stromal cells influence
the growth of normal mammary epithelial cells as well as epithe-
lial carcinogenesis in the mammary gland (Tremblay, 1979; van
den Hoof, 1988; Lippman and Dickson, 1990; Sakakura, 1991).
Our results, at least in part, explain the pathological significance of
elevated levels of PGE2 and HGF in malignant cancer tissues, and
a possible mechanism for tumour–stromal interaction, as mediated
by PGE2 and HGF, which would confer invasive growth potential
in breast cancer. If our thesis is tenable, the disruption of such
mutual interactions between carcinoma cells and stromal fibro-
blasts, as mediated by PGE2 and HGF, may possibly be a unique
therapeutic strategy toward prevention of invasion and metastasis
of breast cancer.
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